NAMS
NewAmsterdam Pharma Company N.V (NAMS) Stock Analysis
Research NewAmsterdam Pharma Company N.V (NAMS) with company financials, earnings context, valuation indicators, risk analysis and related market news.
Research record updated: . Individual measures may refer to different reporting periods.
- Ticker
- NAMS
- Company
- NewAmsterdam Pharma Company N.V
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.60B
- Financial data source
- FMP financial statements + FMP cash flow statements + FMP balance sheet + income statements + StockAnalysis complete statements
- Annual revenue (reporting year not supplied)
- $22.50M
- Annual net income (reporting year not supplied)
- $-203.82M
- Annual free cash flow (reporting year not supplied)
- $-148.03M
- Trailing revenue
- $7.12M
- Trailing net income
- $-259.50M
- Total assets
- $769.28M
- Total liabilities
- $85.85M
NewAmsterdam Pharma Company N.V (NAMS) Stock Analysis research
Review the available company profile, financial history, valuation context and investor signals for NewAmsterdam Pharma Company N.V. Compare the reported operating results with the valuation and risk measures below.
The figures are cached research data and can change after new filings, earnings reports or market updates. Verify material facts with primary company disclosures before making an investment decision.